alkenes has been researched along with Carcinoma, Oat Cell in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
de Jong, RS; de Vries, EG; Groen, HJ; Höppener, FJ; Mulder, NH; Sleijfer, DT; Uges, DR; van der Graaf, WT; Willemse, PH | 1 |
de Jong, S; de Vries, EG; Mulder, NH; Zijlstra, JG | 1 |
1 trial(s) available for alkenes and Carcinoma, Oat Cell
Article | Year |
---|---|
Phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin.
Topics: Adult; Aged; Alanine Transaminase; Alkenes; Antibiotics, Antineoplastic; Aspartate Aminotransferases; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Half-Life; Humans; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Polyenes; Pyrones; Teniposide; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1999 |
1 other study(ies) available for alkenes and Carcinoma, Oat Cell
Article | Year |
---|---|
Lack of cross-resistance to fostriecin in a human small-cell lung carcinoma cell line showing topoisomerase II-related drug resistance.
Topics: Alkenes; Antibiotics, Antineoplastic; Carcinoma, Small Cell; Cell Line; Cell Nucleus; DNA Topoisomerases, Type II; Drug Resistance; Drug Screening Assays, Antitumor; Etoposide; Humans; Lung Neoplasms; Methotrexate; Polyenes; Pyrones; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1991 |